Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 1/1999

01-04-1999 | ORIGINAL ARTICLE

Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells

Authors: Govindaswami Ragupathi, Lisa Howard, Sarah Cappello, R. Rao Koganty, Dongxu Qiu, B. Michael Longenecker, Mark A. Reddish, Kenneth O. Lloyd, Philip O. Livingston

Published in: Cancer Immunology, Immunotherapy | Issue 1/1999

Login to get access
Metadata
Title
Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells
Authors
Govindaswami Ragupathi
Lisa Howard
Sarah Cappello
R. Rao Koganty
Dongxu Qiu
B. Michael Longenecker
Mark A. Reddish
Kenneth O. Lloyd
Philip O. Livingston
Publication date
01-04-1999
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 1/1999
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050542

Other articles of this Issue 1/1999

Cancer Immunology, Immunotherapy 1/1999 Go to the issue

ORIGINAL ARTICLE

CD95 Ligand expression enhances growth of murine renal cell carcinoma in vivo

ORIGINAL ARTICLE

High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition

ORIGINAL ARTICLE

A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu

ORIGINAL ARTICLE

Production and characterization of an anti-(MUC1 mucin) recombinant diabody

ORIGINAL ARTICLE

Lack of evidence for an immunosuppressive role for MUC1

ORIGINAL ARTICLE

Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits